Reviewing Arbutus Biopharma Corporation (ABUS)’s and CollPlant Holdings Ltd. (NASDAQ:CLGN)’s results

We are contrasting Arbutus Biopharma Corporation (NASDAQ:ABUS) and CollPlant Holdings Ltd. (NASDAQ:CLGN) on their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arbutus Biopharma Corporation 6.80M 31.74 83.10M -1.81 0.00
CollPlant Holdings Ltd. N/A 0.00 N/A -1.64 0.00

In table 1 we can see Arbutus Biopharma Corporation and CollPlant Holdings Ltd.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us Arbutus Biopharma Corporation and CollPlant Holdings Ltd.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Arbutus Biopharma Corporation -1,222.06% -72.9% -32.3%
CollPlant Holdings Ltd. 0.00% 0% 0%

Insider and Institutional Ownership

Roughly 43.5% of Arbutus Biopharma Corporation shares are held by institutional investors while 23.69% of CollPlant Holdings Ltd. are owned by institutional investors. About 3.3% of Arbutus Biopharma Corporation’s share are held by insiders. On the other hand, insiders held about 19.13% of CollPlant Holdings Ltd.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Arbutus Biopharma Corporation 2.06% -10.1% -55.5% -25.21% -12.75% -11.88%
CollPlant Holdings Ltd. -22.71% -19.61% -14.29% -20% 0% -48.47%

For the past year Arbutus Biopharma Corporation’s stock price has smaller decline than CollPlant Holdings Ltd.

Summary

CollPlant Holdings Ltd. beats Arbutus Biopharma Corporation on 5 of the 9 factors.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The companyÂ’s lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also comprise ARB-1740, a pan-genotypic second-generation siRNA therapeutic in Phase II multi-dose study in Hepatitis B e antigen-chronic HBV patients; and AB-423, a core protein/capsid assembly inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates, including oral surface antigen inhibitors, cccDNA targeting agents, and immunomodulators. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) in Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and DCR-PH1 for the treatment of primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.

CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen (rhCollagen) that is produced with its proprietary plant based genetic engineering technology. The company's products include Vergenix STR, a soft tissue repair matrix intended for treatment of tendinopathy; Vergenix FG, a wound-filling flowable gel for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; and BioInks for 3D printing of tissues and organs. CollPlant Holdings Ltd. and is headquartered in Ness Ziona, Israel.